Skip Navigation LinksHome > January 2014 - Volume 36 - Issue 1 > Ferrous Sulfate (Fe2+) Had a Faster Effect Than Did Ferric P...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e318299c91a
Original Articles

Ferrous Sulfate (Fe2+) Had a Faster Effect Than Did Ferric Polymaltose (Fe3+) on Increased Oxidant Status in Children With Iron-deficiency Anemia

Aycicek, Ali MD*; Koc, Ahmet MD; Oymak, Yesim MD*; Selek, Sahbettin MD; Kaya, Cemil MD§; Guzel, Bulent MD§

Collapse Box

Abstract

Objective: The purpose of this study was to compare the total oxidant and antioxidant effect of different oral iron preparations in children with iron-deficiency anemia (IDA).

Methods: A total of 65 children with IDA were randomized to receive 5 mg Fe/kg/d iron (II) sulfate (Fe2+ group, n=33) or iron (III)-hydroxide polymaltose complex (Fe3+ group, n=32); healthy controls (n=28) were also included in the study. Serum total thiol (–SH), total antioxidant capacity (TAC), total oxidant status (TOS), oxidative stress index (OSI), and hematological profile were evaluated at the baseline and on day 8 and day 30 of the therapy.

Results: Serum TOS and OSI levels were significantly higher and total –SH and total antioxidant capacity levels were significantly lower in the study groups at the beginning of therapy than in the controls (P>0.001). In multivariate analysis, after controlling for multiple confounding factors, on days 8 and 30, serum TOS and OSI levels were not different in the Fe3+ group, whereas they were significantly reduced in the Fe2+ group (P≤0.033).

Conclusions: Serum total oxidant status was significantly increased in children with IDA, and Fe2+ was highly effective in correcting elevated oxidative status.

© 2014 by Lippincott Williams & Wilkins.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.